CECCON, MONICA
CECCON, MONICA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay
2009 Piazza, R; Redaelli, S; Ceccon, M; Mogavero, A; Marega, M; Mologni, L; Boschelli, F; Pogliani, E; GAMBACORTI PASSERINI, C
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2
2010 Mologni, L; Dekhil, H; Ceccon, M; Purgante, S; Lan, C; Cleris, L; Magistroni, V; Formelli, F; GAMBACORTI PASSERINI, C
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells
2012 Mologni, L; Brussolo, S; Ceccon, M; GAMBACORTI PASSERINI, C
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
2012 Redaelli, S; Mologni, L; Rostagno, R; Piazza, R; Magistroni, V; Ceccon, M; Viltadi, M; Flynn, D; GAMBACORTI PASSERINI, C
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
2013 Ceccon, M; Mologni, L; Bisson, W; Scapozza, L; GAMBACORTI PASSERINI, C
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors
2013 Ceccon, M
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter
2014 Redaelli, S; Perini, P; Ceccon, M; Piazza, R; Rigolio, R; Boschelli, F; Giannoudis, A; GAMBACORTI PASSERINI, C
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients
2014 GAMBACORTI PASSERINI, C; Farina, F; Stasia, A; Redaelli, S; Ceccon, M; Mologni, L; Messa, M; Guerra, L; Giudici, G; Sala, E; Mussolin, L; Deeren, D; King, M; Steurer, M; Ordemann, R; Cohen, A; Grube, M; Bernard, L; Chiriano, G; Antolini, L; Piazza, R
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells
2014 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; Gambacorti-Passerini, C
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
2015 Fontana, D; Ceccon, M; GAMBACORTI PASSERINI, C; Mologni, L
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth
2015 Hoareau Aveilla, C; Valentin, T; Daugrois, C; Quelen, C; Mitou, G; Quentin, S; Jia, J; Spicuglia, S; Ferrier, P; Ceccon, M; Giuriato, S; GAMBACORTI PASSERINI, C; Brousset, P; Lamant, L; Meggetto, F
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
2015 Mologni, L; Ceccon, M; Pirola, A; Chiriano, G; Piazza, R; Scapozza, L; GAMBACORTI PASSERINI, C
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
2015 Redaelli, S; Perini, P; Ceccon, M; Piazza, R; Rigolio, R; Mauri, M; Boschelli, F; Giannoudis, A; GAMBACORTI PASSERINI, C
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors
2015 Mologni, L; Ceccon, M; Fontana, D; Pirola, A; Piazza, R; Gambacorti-Passerini, C
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency
2015 Ceccon, M; Boggio Merlo, M; Mologni, L; Varesio, L; Poggio, T; Menotti, M; Bombelli, S; Rigolio, R; Manazza, A; Ambrogio, C; Giudici, G; Casati, C; Compagno, M; Turner, S; Gambacorti Passerini, C; Chiarle, R; Voena, C
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
2015 Redaelli, S; Ceccon, M; Pirola, A; Peronaci, M; Gambacorti-Passerini, C; Mologni, L
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; GAMBACORTI PASSERINI, C
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
2016 Ceccon, M; Merlo, M; Mologni, L; Poggio, T; Varesio, L; Menotti, M; Bombelli, S; Rigolio, R; Manazza, A; Di Giacomo, F; Ambrogio, C; Giudici, G; Casati, C; Mastini, C; Compagno, M; Turner, S; GAMBACORTI PASSERINI, C; Chiarle, R; Voena, C
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
2016 Redaelli, S; Ceccon, M; Antolini, L; Rigolio, R; Pirola, A; Peronaci, M; GAMBACORTI PASSERINI, C; Mologni, L